The AVP III is a self-expanding nitinol mesh device and is designed to be introduced in a minimally invasive fashion through a catheter. The AVP III is under review by the FDA for clearance to market in the US.
The company also announced the immediate availability and launch of the device in the EU. The Amplatzer Vascular Plug III (AVP III) further expands the company’s family of occlusion devices designed to embolize, or close, blood vessels and blood vessel malformations in the peripheral vasculature.
Franck Gougeon, president and CEO of Aga Medical, said: “Our pre-clinical testing suggests that the AVP III will have the fastest occlusion times within our vascular plug family. Our goal is to provide physicians with a toolbox of embolization devices that can treat vessels of different types and length and with different flow characteristics.”